Optimal implementation of an Ontario nirsevimab program for respiratory syncytial virus (RSV) prophylaxis: Recommendations from a provincial RSV expert panel
Bosco Paes, Vivien Brown, Erin Courtney, Erin Fleischer, Fiona Guy, Eddy Lau, Allan Mills, Julie Toole, Meagan Bardan, Cynthia Wong, Gary Lam, Graeme N. Smith · 2024
Read Optimal implementation of an Ontario nirsevimab program for respiratory syncytial virus (RSV) prophylaxis: Recommendations from a provincial RSV expert panel by Bosco Paes, Vivien Brown, Erin Courtney, Erin Fleischer, Fiona Guy, Eddy Lau, Allan Mills, Julie Toole, Meagan Bardan, Cynthia Wong, Gary Lam, Graeme N. Smith (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11789722.txt.
Description
Bosco Paes and co-authors give expert advice on how Ontario should roll out a drug that guards babies against a common lung virus. Their 2024 panel paper covers nirsevimab, an antibody given to prevent severe disease from respiratory syncytial virus. The panel met after the drug saw its first season of use elsewhere.
Experts from many care roles reviewed how Spain, France, and the United States ran their first programs. They weighed effects on severe illness, hospital load, and system costs. A survey of Ontario providers added local views on how to reach babies born before and during the virus season. The panel agreed on a set of steps for giving the drug in Ontario. The aim is high uptake with a smooth, fair rollout across the province.
Catalog record
| CREATOR | Bosco Paes, Vivien Brown, Erin Courtney, Erin Fleischer, Fiona Guy, Eddy Lau, Allan Mills, Julie Toole, Meagan Bardan, Cynthia Wong, Gary Lam, Graeme N. Smith |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 46 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |